Ipsen

A global specialty-care biopharmaceutical company with three core therapy areas: oncology, rare disease and neuroscience. It combines in-house R&D with business development and partnered commercialization to grow beyond legacy endocrine products.

Company Overview

Ipsen develops and markets prescription medicines, with a portfolio anchored by specialty products in oncology, rare disease and neuroscience. The company has positioned its growth around newer “platform” brands while managing expected erosion in older franchises.

Headquarters and Global Presence

Ipsen is headquartered in France and operates globally across R&D, manufacturing and commercial activities, with products marketed in major regions through a mix of direct operations and partners.

Founding and History

Ipsen is a long-established European pharma company that has reshaped its portfolio over the last decade toward specialty care. David Loew has served as CEO since July 1, 2020.

Therapy Areas and Focus

Ipsen’s current strategic focus is concentrated in:

Oncology
Rare disease
Neuroscience

Technology Platforms and Modalities

Ipsen develops across small molecules and biologics, with increasing emphasis on differentiated specialty assets and lifecycle expansion. In its FY 2025 results update, Ipsen highlighted continued pipeline expansion and integration of assets obtained through business development, including oncology assets from the planned acquisition of ImCheck Therapeutics.

Key Products

Key marketed brands that Ipsen and third-party analysts frequently highlight as growth drivers include Dysport, Cabometyx, Onivyde, Bylvay and Iqirvo, alongside the legacy product Somatuline.

Strategic Partnerships

Ipsen’s commercial and pipeline model relies on partnerships for selected assets and geographies, alongside targeted M&A to add mid-stage and preclinical programs. The company’s 2025 sales update referenced the proposed acquisition of ImCheck Therapeutics as a pipeline-expansion move in oncology.

FAQ Section

Ipsen is a specialty-care biopharma company focused on oncology, rare disease and neuroscience, combining internal R&D with licensing, acquisitions and partner-enabled commercialization to expand its portfolio and manage lifecycle transitions.

Ipsen’s disclosed priority therapy areas are oncology, rare disease and neuroscience, which it reports as distinct growth drivers in its financial reporting.

Ipsen’s portfolio is led by a set of specialty brands often cited as growth platforms (including Dysport, Cabometyx, Onivyde, Bylvay and Iqirvo), while Somatuline remains a significant product but is managed in the context of post-patent dynamics.

Recent developments, in reverse chronological order:

February 12, 2026: Ipsen reported FY 2025 results and provided 2026 guidance; it also highlighted pipeline expansion and outlined multiple expected regulatory and clinical milestones in 2026.
October 22, 2025: Ipsen announced the proposed acquisition of ImCheck Therapeutics, described as adding a first-in-class Phase II asset and expanding the oncology pipeline.

Ipsen’s recent reporting frames growth as coming from performance of newer specialty brands across its three therapy areas, alongside continued pipeline expansion through R&D and business development.

Want to Update your Company's Profile?